Date: Tuesday, December 2, 2025
Time: 11am EST - 12pm EST
Services: Pharmacometrics, Regulatory Submissions
Register
Vice President, Consulting, Certara
Dr. Felix Boakye-Agyeman is Vice President of Pharmacometrics within the Integrated Drug Development (IDD) group at Certara, a global leader in model-informed drug development. Certara partners with more than 2,300 organizations worldwide and has contributed over 99% of all new drug approvals in the past decade.
At Certara, Dr. Boakye-Agyeman leads a multidisciplinary team of scientists who integrate quantitative modeling and clinical pharmacology, and to optimize drug development across therapeutic areas. His work has directly supported the development and approval of multiple therapies, particularly in oncology, immunology, and pediatric indications.
With a background spanning medicine, clinical pharmacology, and quantitative sciences, Dr. Boakye-Agyeman is recognized for advancing model-informed strategies for special and vulnerable populations, ensuring that data-driven innovation translates into safer and more effective therapies.
Prior to joining Certara, he held leadership roles at Synteract, where he oversaw pharmacometric consulting for adult and pediatric programs, and at the Duke Clinical Research Institute (DCRI), supporting early-phase and pediatric trials through the NIH-funded Pediatric Trials Network. His contributions have informed pediatric dosing strategies and labeling updates by major regulatory agencies, including the FDA, EMA, PMDA, NMPA, and Health Canada.
Beyond his role at Certara, Dr. Boakye-Agyeman serves on the Board of Africa Partners Medical (APM), where for over 15 years he has contributed to health system strengthening, medical training, and quality improvement initiatives across Ghana and West Africa.
Functional Expertise
- Population PK
- Exposure Response Analysis
- PK/PD analysis
- Non-compartmental analysis
- Concentration QTc analysis
- Clinical pharmacology
Specialty Areas
- Oncology
- Autoimmune
- Infectious diseases
- Antibody drug conjugates (ADC)
- Special Populations (Pediatrics, Maternal Health)
Sr. Director, Pharmacometrics
Huub is a senior pharmacometrician with an in-depth knowledge of pharma R&D, with 20+ years of pharmaceutical industry / consulting experience. He has a broad regulatory experience reflected by contributions to multiple new drug applications across therapeutic areas. He has proficient modeling skills in population PK, PKPD and exposure-response analysis. Huub has demonstrated ability to successfully lead pharmacometric project teams covering the full chain from scoping, pricing, setting up M&S analysis plans, execution of analysis and authoring regulatory quality reports.
Functional Expertise
- Clinical pharmacology
- DMPK
- Drug development strategy
- Non-compartmental analysis
- PK/PD analysis
- Population PK
Specialty Areas
- Antibody drug conjugates (ADC)
- Central nervous system (CNS)
- Oncology
- Orphan diseases
- Pediatrics
- Psychiatric
VP, Clinical Pharmacology Consulting
Dr Nolan Wood joined Certara in 2017 as a consultant in the clinical pharmacology and translational medicine group, providing clinical pharmacology leadership and stewardship to develop high quality, innovative clinical pharmacology programs supporting global drug development. Dr. Wood has more than 35 years of global drug development experience working in the pharmaceutical industry and as a consultant, covering all stages of development, from first-in-human studies through to regulatory submissions, including pediatric drug development. He has worked across a wide range of therapeutic areas involving both small molecules and biological products. Working as the global clinical pharmacology lead, he has taken responsibility for implementing model-informed drug development strategies resulting in successful global regulatory approvals for several compounds. He has contributed to the design and execution of studies in special populations including patients with renal and hepatic impairment and pediatric populations. Dr. Wood has extensive experience of interactions with the major health authorities and has written Clinical Pharmacology sections for regulatory submissions and requests for information.
Following a degree in Pharmacology, Dr Wood obtained a PhD in the Clinical Pharmacology Group at the University of Southampton. He has (co-) authored over 40 peer-reviewed publications and is a member of the British Pharmacological Society.
Functional Expertise
- Clinical pharmacology
- Drug development strategy
- Drug product development
- Due diligence
- PK/PD analysis
- Model informed drug development
Specialty Areas
- Immunology
- Immuno-oncology
- Infectious diseases
- Oncology
- Pediatrics
- Respiratory
Senior Vice President, Global Quantitative Sciences Services, Certara Drug Development Solutions
Rik de Greef is a Senior VicePresident of Global Quantitative Science Services at Certara. Rik was trained as a PK-PD scientist at Leiden University, The Netherlands. Over the years, Rik has taken on roles with increasing responsibilities within Organon and its successor companies Schering-Plough and Merck/MSD. Most recently, has was site lead for Clinical PK-PD. In this role he has led the expansion of the group from 15 to 34 coworkers. Also, he has led the preparations of the early clinical components of the BLA submission for Merck’s key program in oncology, pembrolizumab.
